Discovery of dihydrochalcone as potential lead for Alzheimer's disease: In Silico and in Vitro study

Citations of this article
Mendeley users who have this article in their library.


By the virtual screening method we have screened out Dihydrochalcone as a top-lead for the Alzheimer's disease using the database of about 32364 natural compounds. The binding affinity of this ligand to amyloid beta (Aβ) fibril has been thoroughly studied by computer simulation and experiment. Using the Thioflavin T (ThT) assay we have obtained the inhibition constant IC50 ≈2:46μM. This result is in good agreement with the estimation of the binding free energy obtained by the molecular mechanic-Poisson Boltzmann surface area method and all-atom simulation with the force field CHARMM 27 and water model TIP3P. Cell viability assays indicated that Dihydrochalcone could effectively reduce the cytotoxicity induced by Aβ. Thus, both in silico and in vitro studies show that Dihydrochalcone is a potential drug for the Alzheimers disease. © 2013 Viet et al.




Viet, M. H., Chen, C. Y., Hu, C. K., Chen, Y. R., & Li, M. S. (2013). Discovery of dihydrochalcone as potential lead for Alzheimer’s disease: In Silico and in Vitro study. PLoS ONE, 8(11).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free